Concepedia

Michael Williams

MW

Statistics

Publications

169

Citations

12.9K

H-Index

59

Active since

1973

Affiliations

Novartis (Switzerland)(Current)

United States Military Academy

Abbott (United Kingdom)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Michael Williams is an author at Novartis (Switzerland) specializing in pharmacology, neuropharmacology, and medicine.

Publications per year

1973–2023

169

Publications

169

The Art of Coding and Thematic Exploration in Qualitative Research

Michael Williams, Tami Moser · International management review · 2019 · 938 citations

Social Sciences, Sociology, Ethnography +11

[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain.

Michael F. Jarvis, Richard Schulz, A. Hutchison et al. · Journal of Pharmacology and Experimental Therapeutics · 1989 · 547 citations

Medicine, Neuroscience, Pharmacology +16

A-317491, a novel potent and selective non-nucleotide antagonist of P2X <sub>3</sub> and P2X <sub>2/3</sub> receptors, reduces chronic inflammatory and neuropathic pain in the rat

Michael F. Jarvis, Edward C. Burgard, Steve McGaraughty et al. · Proceedings of the National Academy of Sciences · 2002 · 466 citations

Medicine, Neurobiology, Pharmacology +17

The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively.

Bruce N. Cronstein, L Daguma, D Nichols et al. · Journal of Clinical Investigation · 1990 · 378 citations · Full text

Life Sciences, Cell Biology, Pharmacology +14

Broad-Spectrum, Non-Opioid Analgesic Activity by Selective Modulation of Neuronal Nicotinic Acetylcholine Receptors

Anthony W. Bannon, Michael Decker, Mark W. Holladay et al. · Science · 1998 · 370 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

1–5 of 169